Chorisia Bark

Chorisia bark (Ceiba speciosa) is a phytochemically rich botanical whose aqueous extract contains HPLC-quantified phenolic compounds—including quercetin, rutin, kaempferol, gallic acid, chlorogenic acid, ellagic acid, and caffeic acid—that confer potent antioxidant (DPPH radical-scavenging) and anti-inflammatory activity. In the landmark study by El-Newary et al. (2020) in Oxidative Medicine and Cellular Longevity (PMCID: PMC7568133), the bark extract significantly inhibited carrageenan-induced paw edema in Wistar rats, with efficacy comparable to the reference drug indomethacin, establishing a pharmacological basis for its traditional anti-inflammatory use.

Origin & History

Chorisia Bark (Ceiba speciosa) is native to the subtropical dry forests and savannah margins of South America, particularly found in Argentina, Brazil, Paraguay, and Bolivia. This resilient tree is valued for its bark's traditional medicinal uses. In functional nutrition, it is recognized for its potential in respiratory support and immune modulation.

Historical & Cultural Context

In traditional Amazonian and Chaco medicine, Chorisia bark is revered as a symbol of cleansing and resilience. Indigenous South American communities traditionally decocted the bark for treating coughs, fevers, and infections, and used it in purifying rituals and healing brews during seasonal transitions or post-illness recovery.

Health Benefits

- **Supports respiratory clarity**: and expectoration, aiding in the management of respiratory ailments.
- **Provides anti-inflammatory and**: antimicrobial actions, contributing to overall immune defense.
- **Assists in detoxification**: processes and traditional fever management.
- **Promotes wound healing**: and tissue regeneration when applied topically.
- **Helps modulate immune**: response, supporting the body's natural defenses.

How It Works

Chorisia bark exerts anti-inflammatory activity via a dual-phase mechanism in the carrageenan-induced inflammation cascade: during the early phase (0–2 hours), flavonoids such as quercetin, rutin, and kaempferol inhibit mast cell degranulation, suppressing the release of histamine, serotonin, and bradykinin. In the late phase (3–5 hours), phenolic acids including gallic acid, chlorogenic acid, and caffeic acid downregulate the cyclooxygenase-2 (COX-2) pathway, reducing prostaglandin E2 (PGE2) synthesis and neutrophil infiltration. The bark's antioxidant mechanism involves direct free radical scavenging by the flavonoid B-ring hydroxyl groups, which donate hydrogen atoms to neutralize DPPH and reactive oxygen species (ROS), while ellagic acid chelates transition metals to prevent Fenton-driven oxidative damage. These synergistic pathways collectively modulate NF-κB signaling and reduce pro-inflammatory cytokine expression (TNF-α, IL-6).

Scientific Research

The most comprehensive pharmacological study on chorisia bark was published by El-Newary et al. (2020) in Oxidative Medicine and Cellular Longevity (PMCID: PMC7568133; DOI: 10.1155/2020/1321354), which used HPLC to identify and quantify seven major phenolic compounds in the aqueous bark extract of Ceiba speciosa. The study employed DPPH radical-scavenging assays to confirm in vitro antioxidant capacity and used a carrageenan-induced paw edema model in Wistar rats to evaluate in vivo anti-inflammatory effects, demonstrating dose-dependent edema inhibition comparable to indomethacin. Additional phytochemical review literature, such as that published in the International Journal of Science and Research Technology, corroborates the presence of flavonoids, tannins, and phenolic acids across multiple Ceiba species. No further indexed PubMed clinical trials specific to chorisia bark have been identified as of 2024, underscoring the need for future human studies.

Clinical Summary

No human clinical trials exist for Chorisia bark specifically, with evidence limited to animal and in vitro studies. Fruit extracts showed significant anti-inflammatory effects (p < 0.0001) at 200-600 mg/kg in carrageenan-induced rat paw edema studies compared to diclofenac controls. Bark aqueous extracts demonstrated glucose toxicity reduction in rats, though antioxidant activity was limited against H₂O₂-induced toxicity despite in vitro antioxidant properties. The current evidence base requires human clinical validation to establish therapeutic efficacy and optimal dosing protocols.

Nutritional Profile

- Phytochemicals: Alkaloids, saponins, tannins, flavonoids, lignans.

Preparation & Dosage

- Common forms: Dried bark (decoction), standardized extracts, herbal syrups, skin salves.
- Preparation: Traditionally decocted for internal use; applied topically for skin conditions.
- Dosage: 1–2 g/day of dried bark in decoction; 300–500 mg/day of standardized extract.

Synergy & Pairings

Role: Polyphenol/antioxidant base
Intention: Immune & Inflammation
Primary Pairings: - Mullein (Verbascum thapsus)
- Eucalyptus (Eucalyptus globulus)
- Pau D'Arco (Handroanthus impetiginosus)
- Licorice (Glycyrrhiza glabra)

Safety & Interactions

No formal human clinical trials or toxicological reports specific to Ceiba speciosa bark extract have been published, so a definitive safety profile has not been established. Given its high content of quercetin, rutin, and other flavonoids, chorisia bark may theoretically interact with anticoagulant or antiplatelet medications (e.g., warfarin, aspirin) by potentiating their effects, and individuals on such therapies should exercise caution. Phenolic acids such as chlorogenic acid are known to influence CYP1A2 and CYP3A4 enzyme activity in vitro, potentially affecting the metabolism of drugs processed through these pathways. Pregnant or breastfeeding individuals should avoid use due to insufficient safety data, and a qualified healthcare provider should be consulted before beginning supplementation.